Back to search results
NCT06627179

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Active, Not Recruiting
PHASE2Ages 8+InterventionalTreatment
Laboratoires Thea
~81 participants
Updated 2026-07-09 on ClinicalTrials.gov
What's tested:Intravitreal Injection of UltevursenNo intervention, will not receive any active study intervention

At a glance

Recruiting sites
0 of 26 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To evaluate efficacy after 24 months of treatment
Measured over 24 Months

Conditions

Retinitis Pigmentosa (RP)
Usher Syndrome Type 2
Deaf Blind
Retinal Disease
Eye Diseases, Hereditary
Eye Disorders Congenital
Vision Disorders

Explore related trials

Retinitis PigmentosaUsher Syndrome Type 2Usherin

NCT06627179

Where you'd take part

This study runs at 26 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Amsterdam University Medical Center - Locatie AMC

    Amsterdam, Netherlandsno site contact published

  • ASST Santi Paolo e Carlo Hospital, University of Milan

    Milan, Italyno site contact published

  • Bascom Palmer Eye Institute/University of Miami

    Miami, Floridano site contact published

  • Baylor College of Medicine

    Houston, Texasno site contact published

  • Casey Eye Institute, Oregon Health & Science University

    Portland, Oregonno site contact published

  • Centre de maladies rares CHNO des Quinze Vingt

    Paris, Franceno site contact published

  • Emory University

    Atlanta, Georgiano site contact published

  • Federal University of São Paulo - Hospital São Paulo (UNIFESP-HSP)

    São Paulo, Brazilno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • To evaluate efficacy after 24 months of treatment24 Months

    Annualized percent change from baseline in ellipsoid zone (EZ) width as measured by spectral-domain optical coherence tomography (SD-OCT) up to Month 24.